David Kirske - 04 Oct 2022 Form 4 Insider Report for CTI BIOPHARMA CORP

Role
EVP, Chief Financial Officer
Signature
David Kirske
Issuer symbol
N/A
Transactions as of
04 Oct 2022
Net transactions value
-$11,193
Form type
4
Filing time
06 Oct 2022, 16:20:45 UTC
Previous filing
03 Oct 2022
Next filing
03 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $1,328 +1,400 +8.3% $0.9489 18,313 04 Oct 2022 Direct
transaction CTIC common stock Sale $8,750 -1,400 -7.6% $6.25 16,913 04 Oct 2022 Direct F1
transaction CTIC common stock Options Exercise $94.89 +100 +0.59% $0.9489 17,013 04 Oct 2022 Direct
transaction CTIC common stock Sale $626 -100 -0.59% $6.26 16,913 04 Oct 2022 Direct F1
transaction CTIC common stock Options Exercise $578 +609 +3.6% $0.9489 17,522 04 Oct 2022 Direct
transaction CTIC common stock Sale $3,818 -609 -3.5% $6.27 16,913 04 Oct 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,400 -0.43% $0.000000 324,967 04 Oct 2022 Common Stock 1,400 $0.9489 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -100 -0.03% $0.000000 324,867 04 Oct 2022 Common Stock 100 $0.9489 Direct F2
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -609 -0.19% $0.000000 324,258 04 Oct 2022 Common Stock 609 $0.9489 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 One third of the shares underlying the option vested on 2/19/20 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.